Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials

This article originally appeared here.
Share this content:
Chemotherapy drug shortages common to oncologists
Chemotherapy drug shortages common to oncologists

(HealthDay News) -- Many cancer patients hold unrealistic hopes when they decide to join early-stage clinical trials of experimental treatments, according to research published online Sept. 26 in Cancer.

Researchers asked 396 cancer patients who were considering enrollment in a phase 1 trial to complete a questionnaire about reasons why they wanted to take part. After meeting with their doctor, 301 patients completed a second questionnaire.

Without a discussion of potential risks and benefits, 43 percent predicted their tumor would shrink. Once they had learned more about the trials, 47 percent predicted their tumor would shrink. The study authors said this percentage is much higher than realistic for early-stage studies. Before talking with their doctor, 72 percent said they would consider enrolling. After a discussion, 84 percent were willing to enroll.

"There is a positive message in this, which is that 84 percent of patients are willing to participate in phase 1 oncology studies after a discussion with clinical and nursing staff who lay out the conservative estimates of benefit and requirements of hospital visits," lead author Udai Banerji, M.D., Ph.D., deputy director of the Drug Development Union at The Institute of Cancer Research in London, said in a journal news release. But, Banerji called the high percentage of cancer patients who expected their tumor to shrink a red flag. "This creates a challenge for health care professionals to manage expectations but to do so without being patronizing or dismissing human hope," he said.

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs